The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study
Open accessAbstract
OBJECTIVES: We explored the effects of B-cell directed therapy in subjects at risk of developing autoantibodypositive rheumatoid arthritis (RA), who never experienced inflammatory arthritis before, and explored biomarkers predictive of arthritis development. METHODS: Individuals positive for both anti-citrullinated peptide antibodies and rheumatoid factor but without arthritis were included in a randomised, double-blind, placebo-controlled study to receive a single infusion of 1000 mg rituximab or placebo. RESULTS: Eighty-one individuals received treatment and were followed up for a mean of 29.0 (0-54) months, during which 30/81 (37%) individuals developed arthritis. The observed risk of developing arthritis in the placebo-treated group was 40%, which was decreased by 55% (HR 0.45, 95% CI 0.154 to 1.322) in the rituximab-treated group at 12 months. Rituximab treatment caused a delay in arthritis development of 12 months compared with placebo treatment at the point when 25% of the subjects had developed arthritis (p<0.0001). Erythrocyte sedimentation rate and the presence of anti-citrullinated α-enolase peptide 1 at baseline were significant predictors of arthritis development. CONCLUSIONS: A single infusion of 1000 mg rituximab significantly delays the development of arthritis in subjects at risk of developing RA, providing evidence for the pathogenetic role of B cells in the earliest, prearthritis stage of autoantibody positive RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Tak, P. P., Doorenspleet, M. E., de Hair, M. J. H., Klarenbeek, P. L., van Beers-Tas, M. H., van Kampen, A. H. C., van Schaardenburg, D., Gerlag, D. M., Baas, F., & de Vries, N. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211351 · Cited by 59
Self-citationRetractedAletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham, C. O., Birnbaum, N. S., Burmester, G. R., Bykerk, V. P., Cohen, M. D., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.138461 · Cited by 4,941
Self-citationEfficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Rantapää‐Dahlqvist, S., de Jong, B. A. W., Berglin, E., Hallmans, G., Wadell, G., Stenlund, H., Sundin, U., & van Venrooij, W. J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11223 · Cited by 1,953
Nielen, M. M. J., van Schaardenburg, D., Reesink, H. W., van de Stadt, R. J., van der Horst‐Bruinsma, I. E., de Koning, M. H. M. T., Habibuw, M. R., Vandenbroucke, J. P., & Dijkmans, B. A. C. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20018 · Cited by 1,861
Emery, P., Fleischmann, R., Filipowicz‐Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., Racewicz, A. J., van Vollenhoven, R. F., Li, N. F., Agarwal, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21778 · Cited by 1,060
Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease
Ellebrecht, C. T., Bhoj, V. G., Nace, A., Choi, E. J., Mao, X., Cho, M. J., Di Zenzo, G., Lanzavecchia, A., Seykora, J. T., Cotsarelis, G., et al. (2016) · Science · doi:10.1126/science.aaf6756 · Cited by 738
Genetic and environmental risk factors for rheumatoid arthritis
Deane, K. D., Demoruelle, M. K., Kelmenson, L. B., Kuhn, K. A., Norris, J. M., & Holers, V. M. (2017) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2017.08.003 · Cited by 666
Tak, P. P., Smeets, T. J. M., Daha, M. R., Kluin, P. M., Meijers, K. A. E., Brand, R., Meinders, A. E., & Breedveld, F. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400206 · Cited by 548
Self-citationGerlag, D. M., Raza, K., van Baarsen, L. G. M., Brouwer, E., Buckley, C. D., Burmester, G. R., Gabay, C., Catrina, A. I., Cope, A. P., Cornelis, F., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200990 · Cited by 470
Self-citation
Cited by
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Lin, Y.-J., Anzaghe, M., & Schülke, S. (2020) · Cells · doi:10.3390/cells9040880 · Cited by 932
The etiology of rheumatoid arthritis
Scherer, H. U., Häupl, T., & Burmester, G. R. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102400 · Cited by 881
Di Matteo, A., Bathon, J. M., & Emery, P. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01525-8 · Cited by 849
The immunology of rheumatoid arthritis
Weyand, C. M., & Goronzy, J. J. (2021) · Nature Immunology · doi:10.1038/s41590-020-00816-x · Cited by 793
Rheumatoid Arthritis — Common Origins, Divergent Mechanisms
Gravallese, E. M., & Firestein, G. S. (2023) · New England Journal of Medicine · doi:10.1056/nejmra2103726 · Cited by 752
Metadata
- Authors
- Gerlag, D. M., Safy, M., Maijer, K. I., Tang, M. W., Tas, S. W., Starmans-Kool, M. J. F., van Tubergen, A., Janssen, M., de Hair, M., Hansson, M., de Vries, N., Zwinderman, A. H., & Tak, P. P.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 78
- Issue
- 2
- Pages
- 179-185
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2903122430
- Cited by
- 295
- References
- 28
- FWCI
- 19.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. https://app.cochat.ai/papers/10.1136/annrheumdis-2017-212763
- The paper
- Gerlag, D. M., Safy, M., Maijer, K. I., Tang, M. W., Tas, S. W., Starmans-Kool, M. J. F., van Tubergen, A., Janssen, M., de Hair, M., Hansson, M., de Vries, N., Zwinderman, A. H., & Tak, P. P. (2019). Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2017-212763
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.